Harnessing Chimeric Degrader Technologies for Antimicrobial Innovation.

Area of Science:

• Microbiology
• Drug Discovery
• Molecular Biology

Background:

• Infectious diseases caused by bacteria and viruses pose a significant global health challenge.
• Emerging drug resistance threatens the efficacy of traditional small-molecule inhibitors.
• Novel therapeutic strategies are urgently needed to combat antimicrobial resistance.

Purpose of the Study:

• To explore recent advances in targeted degradation approaches for infectious diseases.
• To highlight the potential of PROTACs and related technologies in anti-infective therapy.
• To discuss future perspectives and design considerations for translating targeted degradation into clinical use.

Main Methods:

• Review of targeted protein and RNA degradation technologies.
• Focus on PROTACs (proteolysis-targeting chimeras) and their variants (BacPROTACs, homo-BacPROTACs).
• Exploration of other degradation modalities like AUTACs, RIBOTACs, and PINADs.

Main Results:

• Targeted degradation offers advantages over traditional inhibition, including catalytic activity and targeting 'undruggable' molecules.
• These approaches show promise for overcoming drug resistance in bacterial and viral infections.
• Clinical success in oncology provides a foundation for anti-infective applications.

Conclusions:

• Targeted degradation represents a promising new frontier in anti-infective drug development.
• Further research and design considerations are crucial for clinical translation.
• These novel modalities could provide effective solutions against resistant bacterial and viral pathogens.